Reneo Pharmaceuticals Inc (RPHM)
1.85
-0.04
(-2.12%)
USD |
NASDAQ |
May 22, 14:21
Reneo Pharmaceuticals Cash from Financing (TTM): 59.86M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 59.86M |
December 31, 2023 | 60.86M |
September 30, 2023 | 65.32M |
June 30, 2023 | 65.24M |
March 31, 2023 | 1.474M |
December 31, 2022 | 0.471M |
September 30, 2022 | 0.265M |
Date | Value |
---|---|
June 30, 2022 | 0.39M |
March 31, 2022 | 86.19M |
December 31, 2021 | 132.41M |
September 30, 2021 | 179.48M |
June 30, 2021 | 179.31M |
March 31, 2021 | 93.47M |
December 31, 2020 | 47.27M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.265M
Minimum
Sep 2022
179.48M
Maximum
Sep 2021
69.43M
Average
63.05M
Median
Cash from Financing (TTM) Benchmarks
Mirum Pharmaceuticals Inc | 324.82M |
NovaBay Pharmaceuticals Inc | 1.313M |
Palatin Technologies Inc | 14.71M |
iBio Inc | 14.24M |
Theriva Biologics Inc | 0.68M |